Teva, Sun Pharma to pay $2.15 billion to settle patent suit
None
Pfizer Inc said Teva Pharmaceuticals Industries Ltd and Sun Pharmaceutical Industries Ltd would pay $2.15 billion to settle a patent suit related to its acid-reflux drug.
This is the first instance of generic drugmakers paying damages for marketing a copy of an existing drug for which patents have yet to expire - known as an 'at-risk' launch. (Reuters)
